Tailoring Treatment Approaches in Psoriasis Management - Episode 12
Dosing Interval Differences in Psoriasis and Psoriatic Arthritis Treatment
Panelists discuss how although SPECTREM was groundbreaking as the first randomized controlled trial specifically targeting moderate psoriasis in high-impact areas, other valuable evidence exists including subgroup analyses from pivotal trials of interleukin-17 inhibitors (secukinumab, ixekizumab, brodalumab) showing efficacy for scalp and nail psoriasis, dedicated studies like GESTURE (secukinumab for palmoplantar psoriasis), IXORA-Q (ixekizumab for genital psoriasis), data on TNF inhibitors for inverse/intertriginous disease, and observational real-world evidence supporting various biologics for difficult-to-treat locations—though most preceding studies were limited by focusing on patients with higher overall body surface area rather than the clinically important population with limited but high-impact disease that SPECTREM specifically addressed.
Video content above is prompted by the following:
- SPECTREM was the first randomized controlled trial to evaluate biologics in this patient population. What other clinical trial data are there on the use of biologics for difficult-to-treat areas?
